Now Available: Final Rule for FDAAA 801 and NIH Policy on Clinical Trial Reporting
60 studies found for:    "Fragile X syndrome"
Show Display Options
RSS Create an RSS feed from your search for:
"Fragile X syndrome"
Need help? See RSS Feeds
Choose a feed type:
Show studies that were first received in the last 14 daysShow studies that were first received in the last 14 days
Show studies added or modified in the last 14 daysShow studies that were added or modified in the last 14 days
Rank Status Study
1 Completed Safety and Efficacy of AFQ056 in Adult Patients With Fragile X Syndrome
Condition: Fragile X Syndrome
Interventions: Drug: AFQ056;   Drug: Placebo
2 Completed
Has Results
Safety and Efficacy of AFQ056 in Adolescent Patients With Fragile X Syndrome
Condition: Fragile X Syndrome
Interventions: Drug: AFQ056;   Drug: Placebo
3 Recruiting Study of Acamprosate in Fragile x Syndrome
Condition: Fragile X Syndrome
Interventions: Drug: acamprosate;   Drug: Placebo
4 Terminated An Open Label Extension Study of STX209 in Subjects With Fragile X Syndrome
Condition: Fragile X Syndrome
Intervention: Drug: Arbaclofen
5 Completed Efficacy and Safety Study of STX209 (Arbaclofen) for Social Withdrawal in Adolescents and Adults With Fragile X Syndrome
Condition: Fragile X Syndrome
Interventions: Drug: arbaclofen;   Drug: placebo
6 Completed A 6-week, Study of MG01CI Low Dose and High Dose Compared With Placebo in Adults and Adolescents With Fragile X Syndrome
Condition: Fragile X Syndrome
Intervention: Drug: MG01CI extended-release tablet
7 Completed Clinical Study to Assess the Pharmacokinetics, Safety and Tolerability of Single and Multiple Oral Doses of AFQ056 in Children With Fragile X Syndrome (FXS)
Condition: Fragile X Syndrome
Intervention: Drug: AFQ056
8 Completed
Has Results
Trial of Minocycline to Treat Children With Fragile X Syndrome
Condition: Fragile X Syndrome
Interventions: Drug: minocycline hydrochloride;   Drug: Placebo
9 Completed Acamprosate in Youth With Fragile X Syndrome
Conditions: Fragile X Syndrome;   Autism Spectrum Disorders
Intervention: Drug: Acamprosate
10 Completed
Has Results
Safety, Tolerability and Efficacy Study of STX209 in Subjects With Fragile X Syndrome
Condition: Fragile X Syndrome
Interventions: Drug: STX209;   Drug: Placebo
11 Completed Trial of Sertraline to Treat Children With Fragile X Syndrome
Condition: Fragile X Syndrome
Interventions: Drug: Sertraline;   Drug: Placebo
12 Completed Effects of CX516 on Functioning in Fragile X Syndrome and Autism
Conditions: Fragile X Syndrome;   Autism
Intervention: Drug: CX516 (Ampalex®)
13 Completed Riluzole in Fragile X Syndrome
Condition: Fragile X Syndrome
Intervention: Drug: Riluzole
14 Recruiting Decisional Capacity and Informed Consent in Fragile X Syndrome
Condition: Fragile X Syndrome (FXS)
Interventions: Other: Paper-Based Informed Consent;   Device: Tablet-Based Consent
15 Active, not recruiting Ganaxolone Treatment in Children With Fragile X Syndrome
Condition: Fragile x Syndrome
Interventions: Drug: Ganaxolone;   Drug: Placebo
16 Completed Safety and Efficacy Study of Antioxidants for the Treatment of the Fragile X Syndrome
Condition: Fragile X Syndrome
Interventions: Dietary Supplement: Ascorbic Acid (Vitamin C) and Alpha-tocopherol (Vitamin E);   Dietary Supplement: Placebo
17 Completed An Open-Label Trial of Donepezil in Fragile X Syndrome
Condition: Fragile X Syndrome
Intervention: Drug: donepezil
18 Completed
Has Results
Add-on Pilot Trial of Minocycline to Treat Fragile X Syndrome
Condition: Fragile X Syndrome
Intervention: Drug: Minocycline
19 Completed
Has Results
Double-blind Placebo Controlled Study of Oxytocin in Fragile X Syndrome
Condition: Fragile X Syndrome
Interventions: Drug: placebo;   Drug: oxytocin 24IU;   Drug: oxytocin 48IU
20 Completed A Safety Study of NNZ-2566 in Patients With Fragile X Syndrome
Condition: Fragile X Syndrome
Interventions: Drug: NNZ-2566;   Drug: Placebo

   Previous Page Studies Shown (1-20) Next Page (21-40) Show next page of results    Last Page
Study has passed its completion date and status has not been verified in more than two years.